Cargando…

A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer

The present study established systems to predict the chemo-sensitivity of muscle invasive bladder cancer (MIBC) for neoadjuvant chemotherapy (NAC) with methotrexate, vinblastine, doxorubicin plus cisplatin (M-VAC) and carboplatin plus gemcitabine (CaG) by analyzing microarray data. The primary aim o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Yoichiro, Zembutsu, Hitoshi, Takata, Ryo, Matsuura, Tomohiko, Kato, Renpei, Kanehira, Mitsugu, Iwasaki, Kazuhiro, Yamada, Noriyuki, Katagiri, Toyomasa, Sugai, Tamotsu, Fujioka, Tomoaki, Nakamura, Yusuke, Obara, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176418/
https://www.ncbi.nlm.nih.gov/pubmed/30333861
http://dx.doi.org/10.3892/ol.2018.9330
_version_ 1783361698425470976
author Kato, Yoichiro
Zembutsu, Hitoshi
Takata, Ryo
Matsuura, Tomohiko
Kato, Renpei
Kanehira, Mitsugu
Iwasaki, Kazuhiro
Yamada, Noriyuki
Katagiri, Toyomasa
Sugai, Tamotsu
Fujioka, Tomoaki
Nakamura, Yusuke
Obara, Wataru
author_facet Kato, Yoichiro
Zembutsu, Hitoshi
Takata, Ryo
Matsuura, Tomohiko
Kato, Renpei
Kanehira, Mitsugu
Iwasaki, Kazuhiro
Yamada, Noriyuki
Katagiri, Toyomasa
Sugai, Tamotsu
Fujioka, Tomoaki
Nakamura, Yusuke
Obara, Wataru
author_sort Kato, Yoichiro
collection PubMed
description The present study established systems to predict the chemo-sensitivity of muscle invasive bladder cancer (MIBC) for neoadjuvant chemotherapy (NAC) with methotrexate, vinblastine, doxorubicin plus cisplatin (M-VAC) and carboplatin plus gemcitabine (CaG) by analyzing microarray data. The primary aim of the study was to investigate whether the clinical response would increase by combining these prediction systems. Treatment of each MIBC case was allocated into M-VAC NAC, CaG NAC, surgery, or radiation therapy groups by their prediction score (PS), which was calculated using the designed chemo-sensitivity prediction system. The therapeutic effect of the present study was compared with the results of historical controls (n=76 patients) whose treatments were not allocated using the chemo-sensitivity prediction system. In addition, the overall survival between the predicted to be responder (positive PS) group and predicted to be non-responder (negative PS) group was investigated in the present study. Of the 33 patients with MIBC, 25 cases were positive PS and 8 were negative PS. Among the 25 positive PS cases, 7 were allocated to receive M-VAC NAC and 18 were allocated to receive CaG NAC according to the results of the prediction systems. Of the 8 negative PS cases, 3 received CaG NAC, 1 received surgery without NAC and 4 received radiation therapy. The total clinical response to NAC was 88.0% (22/25), which was significantly increased compared with the historical controls [56.6% (43/76) P=0.0041]. Overall survival of the positive PS group in the study was significantly increased compared with the negative PS group (P=0.027). In conclusion, the combination of the two prediction systems may increase the treatment efficacy for patients with MIBC by proposing the optimal NAC regimen. In addition, the positive PS group would have a better prognosis compared with the negative PS group. These results suggest that the two prediction systems may lead to the achievement of ‘precision medicine’.
format Online
Article
Text
id pubmed-6176418
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-61764182018-10-17 A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer Kato, Yoichiro Zembutsu, Hitoshi Takata, Ryo Matsuura, Tomohiko Kato, Renpei Kanehira, Mitsugu Iwasaki, Kazuhiro Yamada, Noriyuki Katagiri, Toyomasa Sugai, Tamotsu Fujioka, Tomoaki Nakamura, Yusuke Obara, Wataru Oncol Lett Articles The present study established systems to predict the chemo-sensitivity of muscle invasive bladder cancer (MIBC) for neoadjuvant chemotherapy (NAC) with methotrexate, vinblastine, doxorubicin plus cisplatin (M-VAC) and carboplatin plus gemcitabine (CaG) by analyzing microarray data. The primary aim of the study was to investigate whether the clinical response would increase by combining these prediction systems. Treatment of each MIBC case was allocated into M-VAC NAC, CaG NAC, surgery, or radiation therapy groups by their prediction score (PS), which was calculated using the designed chemo-sensitivity prediction system. The therapeutic effect of the present study was compared with the results of historical controls (n=76 patients) whose treatments were not allocated using the chemo-sensitivity prediction system. In addition, the overall survival between the predicted to be responder (positive PS) group and predicted to be non-responder (negative PS) group was investigated in the present study. Of the 33 patients with MIBC, 25 cases were positive PS and 8 were negative PS. Among the 25 positive PS cases, 7 were allocated to receive M-VAC NAC and 18 were allocated to receive CaG NAC according to the results of the prediction systems. Of the 8 negative PS cases, 3 received CaG NAC, 1 received surgery without NAC and 4 received radiation therapy. The total clinical response to NAC was 88.0% (22/25), which was significantly increased compared with the historical controls [56.6% (43/76) P=0.0041]. Overall survival of the positive PS group in the study was significantly increased compared with the negative PS group (P=0.027). In conclusion, the combination of the two prediction systems may increase the treatment efficacy for patients with MIBC by proposing the optimal NAC regimen. In addition, the positive PS group would have a better prognosis compared with the negative PS group. These results suggest that the two prediction systems may lead to the achievement of ‘precision medicine’. D.A. Spandidos 2018-11 2018-08-20 /pmc/articles/PMC6176418/ /pubmed/30333861 http://dx.doi.org/10.3892/ol.2018.9330 Text en Copyright: © Kato et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Kato, Yoichiro
Zembutsu, Hitoshi
Takata, Ryo
Matsuura, Tomohiko
Kato, Renpei
Kanehira, Mitsugu
Iwasaki, Kazuhiro
Yamada, Noriyuki
Katagiri, Toyomasa
Sugai, Tamotsu
Fujioka, Tomoaki
Nakamura, Yusuke
Obara, Wataru
A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer
title A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer
title_full A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer
title_fullStr A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer
title_full_unstemmed A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer
title_short A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer
title_sort prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176418/
https://www.ncbi.nlm.nih.gov/pubmed/30333861
http://dx.doi.org/10.3892/ol.2018.9330
work_keys_str_mv AT katoyoichiro aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT zembutsuhitoshi aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT takataryo aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT matsuuratomohiko aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT katorenpei aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT kanehiramitsugu aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT iwasakikazuhiro aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT yamadanoriyuki aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT katagiritoyomasa aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT sugaitamotsu aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT fujiokatomoaki aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT nakamurayusuke aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT obarawataru aprospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT katoyoichiro prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT zembutsuhitoshi prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT takataryo prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT matsuuratomohiko prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT katorenpei prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT kanehiramitsugu prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT iwasakikazuhiro prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT yamadanoriyuki prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT katagiritoyomasa prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT sugaitamotsu prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT fujiokatomoaki prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT nakamurayusuke prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT obarawataru prospectivestudytoexaminetheaccuraciesandefficaciesofpredictionsystemsforresponsetoneoadjuvantchemotherapyformuscleinvasivebladdercancer